Trading the drug price controversy hitting biotech

Prescription drugs
Ingram Publishing | Getty Images

Indexes representing the biotech and health-care sectors are down 15 percent and 7 percent, respectively, compared to an S&P 500 off 3 percent since the news was released Sept. 21 that Hillary Clinton plans to regulate drug pricing.

Investors are wondering which health-care and biotech names are most at risk from potential drug pricing regulation. Or at the very least, the companies that could come under scrutiny from both parties in Congress over the practice of extreme price increases on older or rare drugs.

Morgan Stanley analyzed the issue and found the companies that were the best and worst positioned in a note sent to clients Thursday.

Contact Investing


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    Get these newsletters delivered to your inbox, and more info about our products and service. Privacy Policy.